Jenburkt Pharmaceuticals Limited (BOM:524731)
India · Delayed Price · Currency is INR 1,077.55
+26.40 (2.51%)
At close: Jul 27, 2026
Jenburkt Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 347.36 | 320.61 | 259.77 | 246.07 | 222.97 |
Depreciation & Amortization | 31.08 | 25.2 | 20.63 | 21.28 | 17 |
Other Amortization | - | 2.08 | 2.77 | 1.31 | 1.98 |
Loss (Gain) From Sale of Assets | 0.45 | 0.34 | 0.19 | 0.49 | -0.33 |
Loss (Gain) From Sale of Investments | -5.26 | -8.58 | -1.33 | -0.04 | -0.02 |
Provision & Write-off of Bad Debts | -18.68 | 0.79 | 12.88 | 5.93 | 0.84 |
Other Operating Activities | -59.82 | -66.32 | -31.5 | -44.02 | -41.82 |
Change in Accounts Receivable | -10.44 | -11.45 | -36.86 | -15.87 | -10.45 |
Change in Inventory | -47.53 | -3.19 | -2.24 | 15.5 | -23.06 |
Change in Accounts Payable | -0.56 | 18.98 | 1.6 | -10.14 | 25.18 |
Change in Other Net Operating Assets | 28.6 | 0.6 | -144.68 | -49.99 | -99.57 |
Operating Cash Flow | 265.22 | 279.06 | 81.24 | 170.52 | 92.71 |
Operating Cash Flow Growth | -4.96% | 243.51% | -52.36% | 83.92% | -52.34% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -137.17 | -197.14 | -25.54 | -21.05 | -30.54 |
Sale of Property, Plant & Equipment | 0.08 | - | - | 0 | 5.06 |
Investment in Securities | -75.17 | 1,501 | 1,204 | 31.84 | -37.3 |
Other Investing Activities | 17.76 | -1,474 | -1,184 | 15.38 | 50.75 |
Investing Cash Flow | -194.5 | -170.45 | -5.8 | 26.18 | -12.02 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Repaid | -6.4 | -5.61 | -5.1 | -5.1 | -5.1 |
Net Debt Issued (Repaid) | -6.4 | -5.61 | -5.1 | -5.1 | -5.1 |
Repurchase of Common Stock | - | - | - | -145.15 | - |
Common Dividends Paid | -79.39 | -67.81 | -63.18 | -55 | -46.8 |
Other Financing Activities | -2.8 | -2.8 | -2.5 | -5.17 | -3.41 |
Financing Cash Flow | -88.59 | -76.22 | -70.78 | -210.41 | -55.31 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | -17.88 | 32.39 | 4.66 | -13.71 | 25.38 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 128.05 | 81.92 | 55.7 | 149.48 | 62.17 |
Free Cash Flow Growth | 56.30% | 47.09% | -62.74% | 140.43% | -66.05% |
Free Cash Flow Margin | 7.59% | 5.40% | 3.92% | 10.93% | 5.01% |
Free Cash Flow Per Share | 29.02 | 18.56 | 12.62 | 32.74 | 13.55 |
Levered Free Cash Flow | 119.91 | 87.39 | 182.75 | 131.18 | 143.35 |
Unlevered Free Cash Flow | 122.8 | 89.76 | 184.19 | 133.05 | 145.52 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 2.8 | 2.8 | 2.5 | 5.16 | 3.41 |
Cash Income Tax Paid | 117.89 | 134.33 | 82.63 | 82.24 | 75.61 |
Change in Working Capital | -29.92 | 4.94 | -182.17 | -60.5 | -107.91 |